Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 0.129 USD 4.37% Market Closed
Market Cap: 18.6m USD

Applied Therapeutics Inc
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Applied Therapeutics Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Net Issuance of Common Stock
$137k
CAGR 3-Years
-83%
CAGR 5-Years
-75%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Issuance of Common Stock
-$1.2B
CAGR 3-Years
3%
CAGR 5-Years
-16%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Issuance of Common Stock
-$2.2B
CAGR 3-Years
-123%
CAGR 5-Years
-191%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Issuance of Common Stock
-$3.5B
CAGR 3-Years
-62%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
18.6m USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
Not Available

See Also

What is Applied Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
137k USD

Based on the financial report for Sep 30, 2025, Applied Therapeutics Inc's Net Issuance of Common Stock amounts to 137k USD.

What is Applied Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-75%

Over the last year, the Net Issuance of Common Stock growth was -100%. The average annual Net Issuance of Common Stock growth rates for Applied Therapeutics Inc have been -83% over the past three years , -75% over the past five years .

Back to Top